Genomic Profiling and Predicting Treatment Response in Acute Myeloid Leukemia

Long non-coding RNA LINC01268 promotes cell growth and inhibits cell apoptosis by modulating miR-217/SOS1 axis in acute myeloid leukemia

“…Given the limited therapeutic methods and poor prognosis of AML patients, it is urgent to find new therapies for AML (5,6). lncRNAs have been reported to be critical for regulating gene expression, and their roles in the progress of AML have received much attention in recent years (8).…”

“…The general feature of AML is aberrant proliferation and differentiation of hematopoietic progenitor cells in the bone marrow, peripheral blood, or other tissues (2,3). For more than four decades, the standard therapy of AML includes chemotherapy (e.g., the combination of an anthracycline and cytarabine) and allogeneic stem cell transplantation (4,5). Despite the improvements in the outcomes for younger AML patients, the prognosis of the older AML patients remains poor (6).…”

“…Despite the improvements in the outcomes for younger AML patients, the prognosis of the older AML patients remains poor (6). The five-year overall survival is below 50% for AML patients under the age of 60, and less than 20% for older patients (5). Therefore, new therapies are urgently needed to improve the outcome, and particularly, targeted therapies have attracted attention.…”

A‐kinase interacting protein 1 might serve as a novel biomarker for worse prognosis through the interaction of chemokine (C‐X‐C motif) ligand 1/chemokine (C‐X‐C motif) ligand 2 in acute myeloid leukemia

“…According to the most recent global statistics report, the incidence and mortality of leukemia account for 2.4% and 3.2% of all cancers, and acute myeloid leukemia (AML), as the most common acute leukemia, is characterized by the accumulation of immature and nonfunctional myeloid precursor cells in the blood and bone marrow . Current therapies, such as chemotherapy and allogeneic stem cell transplantation, bring in improvements to the survival rate in patients with AML, while the majority of patients with AML still experience unfavorable prognosis with below 50% 5‐year overall survival (OS) . Besides, patients with AML experience heterogeneous responses and outcomes to the treatments which make the exploration of markers for prognosis necessary.…”

“…1,2 Current therapies, such as chemotherapy and allogeneic stem cell transplantation, bring in improvements to the survival rate in patients with AML, while the majority of patients with AML still experience unfavorable prognosis with below 50% 5-year overall survival (OS). 3 Besides, patients with AML experience heterogeneous responses and outcomes to the treatments which make the exploration of markers for prognosis necessary. Therefore, it is essential to discover novel molecular markers which would serve as novel prognostic indexes and guide AML management in the future.…”